These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 29556838)

  • 41. Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study.
    Anderson LJ; Henley W; Wyatt KM; Nikolaou V; Waldek S; Hughes DA; Lachmann RH; Logan S
    J Inherit Metab Dis; 2014 Nov; 37(6):945-52. PubMed ID: 24906254
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up.
    Spiridigliozzi GA; Heller JH; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):22-9. PubMed ID: 22253038
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy.
    Terzis G; Krase A; Papadimas G; Papadopoulos C; Kavouras SA; Manta P
    Mol Genet Metab; 2012 Dec; 107(4):669-73. PubMed ID: 23146291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of interrupting enzyme replacement therapy in late-onset Pompe disease.
    Wenninger S; Gutschmidt K; Wirner C; Einvag K; Montagnese F; Schoser B
    J Neurol; 2021 Aug; 268(8):2943-2950. PubMed ID: 33625582
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
    Kroos MA; Pomponio RJ; Hagemans ML; Keulemans JL; Phipps M; DeRiso M; Palmer RE; Ausems MG; Van der Beek NA; Van Diggelen OP; Halley DJ; Van der Ploeg AT; Reuser AJ
    Neurology; 2007 Jan; 68(2):110-5. PubMed ID: 17210890
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enzyme replacement therapy for Pompe disease.
    Angelini C; Semplicini C
    Curr Neurol Neurosci Rep; 2012 Feb; 12(1):70-5. PubMed ID: 22002767
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
    Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
    J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease.
    van Kooten HA; Ditters IAM; Hoogeveen-Westerveld M; Jacobs EH; van den Hout JMP; van Doorn PA; Pijnappel WWMP; van der Ploeg AT; van der Beek NAME
    Orphanet J Rare Dis; 2022 Feb; 17(1):31. PubMed ID: 35109913
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years.
    Stepien KM; Hendriksz CJ; Roberts M; Sharma R
    Mol Genet Metab; 2016 Apr; 117(4):413-8. PubMed ID: 26873529
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early-onset of symptoms and clinical course of Pompe disease associated with the c.-32-13 T > G variant.
    Herbert M; Case LE; Rairikar M; Cope H; Bailey L; Austin SL; Kishnani PS
    Mol Genet Metab; 2019 Feb; 126(2):106-116. PubMed ID: 30655185
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation.
    Desai AK; Walters CK; Cope HL; Kazi ZB; DeArmey SM; Kishnani PS
    Mol Genet Metab; 2018 Feb; 123(2):92-96. PubMed ID: 29289479
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ocular and histologic findings in a series of children with infantile pompe disease treated with enzyme replacement therapy.
    Prakalapakorn SG; Proia AD; Yanovitch TL; DeArmey S; Mendelsohn NJ; Aleck KA; Kishnani PS
    J Pediatr Ophthalmol Strabismus; 2014; 51(6):355-62. PubMed ID: 25139343
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pulmonary outcome measures in long-term survivors of infantile Pompe disease on enzyme replacement therapy: A case series.
    ElMallah MK; Desai AK; Nading EB; DeArmey S; Kravitz RM; Kishnani PS
    Pediatr Pulmonol; 2020 Mar; 55(3):674-681. PubMed ID: 31899940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
    Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F
    Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase.
    van Capelle CI; Poelman E; Frohn-Mulder IM; Koopman LP; van den Hout JMP; Régal L; Cools B; Helbing WA; van der Ploeg AT
    Int J Cardiol; 2018 Oct; 269():104-110. PubMed ID: 30049495
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy.
    McIntosh PT; Hobson-Webb LD; Kazi ZB; Prater SN; Banugaria SG; Austin S; Wang R; Enterline DS; Frush DP; Kishnani PS
    Mol Genet Metab; 2018 Feb; 123(2):85-91. PubMed ID: 29050825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiopulmonary exercise test to quantify enzyme replacement response in pediatric Pompe disease.
    Bar-Yoseph R; Mandel H; Mainzer G; Gur M; Tal G; Shalloufeh G; Bentur L
    Pediatr Pulmonol; 2018 Mar; 53(3):366-373. PubMed ID: 29356433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantification of muscle pathology in infantile Pompe disease.
    Schänzer A; Kaiser AK; Mühlfeld C; Kulessa M; Paulus W; von Pein H; Rohrbach M; Viergutz L; Mengel E; Marquardt T; Neubauer B; Acker T; Hahn A
    Neuromuscul Disord; 2017 Feb; 27(2):141-152. PubMed ID: 27927596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of enzyme replacement therapy on bone density in late onset Pompe disease.
    Avanti M; Martin A; Columbres RC; Mozaffar T; Kimonis V
    Mol Genet Metab; 2023 Nov; 140(3):107644. PubMed ID: 37515933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.